daptomycin · Baxter Hlthcare Corp · NDA 213645
Daptomycin In 0.9% Sodium Chloride
Earliest generic entry, as listed · earliest of 4 marketed strengths
Open now
No unexpired patents or exclusivities are listed for this product.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 4
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 213645 · 002 · RLD | solution, intravenous | 350MG/50ML (7MG/ML) | open |
| 213645 · 003 · RLD | solution, intravenous | 500MG/50ML (10MG/ML) | open |
| 213645 · 004 · RLD | solution, intravenous | 700MG/100ML (7MG/ML) | open |
| 213645 · 005 · RLD | solution, intravenous | 1GM/100ML (10MG/ML) | open |